Brief: Genprex Receives Safety Review Committee Approval To Advance To Phase 2 Expansion Portion Of Acclaim-1 Clinical Trial Of Reqorsa® In Combination With Tagrisso® In Advanced Non-Small Cell Lung Cancer
30/05/2023 12:48
May 30 (Reuters) - Genprex Inc GNPX.O :
* GENPREX RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO
ADVANCE TO
PHASE 2 EXPANSION PORTION OF ACCLAIM-1 CLINICAL TRIAL OF
REQORSA® IN COMBINATION WITH TAGRISSO® IN ADVANCED NON-SMALL
CELL LUNG CANCER
* GENPREX INC - RESULTS FROM PHASE 1 PORTION INDICATE
FAVORABLE
SAFETY PROFILE OF NOVEL GENE THERAPY IN SOLID TUMOR CANCER
Source text for Eikon: ID:nPn4NVz3ma
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy